Changzhou Qianhong Bio-pharma Co. Ltd, a biochemical maker of polysaccharides and enzymes drugs, has commenced construction of phase two of its pharmaceuticals production facility at Changzhou National Hi-Tech District on November 28, it was reported Tuesday.

The company has invested CNY1bn and phase two adds 200 million tablets and 60 million injections to production, making molecular diagnosis reagents available for use by 20 million people.

The CNY1.2bn phase one project, which is already in operation, generated sales revenue of CNY1,070m in 2017. Phase two, in line with international standards, will concentrate on the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights, with the aim of treating patients with critical illnesses such as cancers and cardiovascular and cerebrovascular diseases.